Novel approaches to treatment of leiomyosarcomas
Ian M Collins1, David M Thomas
1Division of Cancer Medicine, Peter MacCallum Cancer Center, St. Andrew's Place, East Melbourne, Victoria 3002, Australia. ian.collins@petermac.org
Abstract:
Soft tissue sarcomas are rare tumors and include subtypes with variable clinical, pathological, and genetic characteristics, including leiomyosarcoma. Current chemotherapy options include the use of doxorubicin, ifosfamide, gemcitabine and docetaxel, and trabectedin, but these have poor response rates in the metastatic setting. While some targeted therapies with tyrosine kinase inhibitors have shown promise, there is a clear need for novel, targeted strategies for this enigmatic form of soft-tissue sarcoma. The genomic instability and multiple, complex karyotypic abnormalities of leiomyosarcomas is a potential for therapy with agents with proven activity in other cancers with genomic instability, such as BRCA-related breast or ovarian cancer. There are few pathways affected in leiomyosarcoma that suggest obvious opportunities, but poly ADP-ribose polymerase (PARP) inhibitors hold promise. This article outlines current therapeutic options available and undergoing study, as well as explores the rationale for the study of PARP inhibitors in leiomyosarcomas, with or without chemotherapy.
Insights
Leiomyosarcoma, a rare soft tissue sarcoma, has limited treatment options. Poly ADP-ribose polymerase (PARP) inhibitors show promise as a novel targeted therapy due to the cancer's genomic instability.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Soft tissue sarcomas, including leiomyosarcoma, are rare with poor response rates to current metastatic chemotherapies.
- Existing treatments like doxorubicin and trabectedin offer limited efficacy.
- There is a critical need for novel, targeted therapeutic strategies for leiomyosarcoma.
Purpose of the Study:
- To review current and emerging therapeutic options for leiomyosarcoma.
- To explore the potential of poly ADP-ribose polymerase (PARP) inhibitors as a targeted therapy.
- To investigate the rationale for using PARP inhibitors in leiomyosarcoma, potentially with chemotherapy.
Main Methods:
- Literature review of current chemotherapy and targeted therapies for soft tissue sarcomas.
- Analysis of the genomic instability and karyotypic abnormalities in leiomyosarcomas.
- Exploration of PARP inhibitor mechanisms and efficacy in cancers with similar genetic profiles.
Main Results:
- Current chemotherapy options demonstrate poor response rates in metastatic leiomyosarcoma.
- Genomic instability in leiomyosarcoma suggests potential therapeutic targets.
- PARP inhibitors represent a promising avenue for novel targeted therapy.
Conclusions:
- Novel targeted therapies are urgently needed for leiomyosarcoma.
- PARP inhibitors hold significant promise for treating leiomyosarcoma, leveraging its genomic instability.
- Further clinical studies of PARP inhibitors in leiomyosarcoma are warranted.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...